Start here if you're new
what it is
Zoetis sells medicines, vaccines, diagnostics, and testing tools for pets and farm animals.
how it gets paid
Last year Zoetis made $9.5B in revenue. U.S. companion animal was the main engine at $3.40B, or 36% of sales.
why it's growing
Revenue grew 2.3% last year. Quarterly sales were $2.387B in Q4 2025, and management said cost cuts and efficiency gains helped offset softer top-line demand.
what just happened
Zoetis posted Q4 adjusted EPS of $1.48, ahead of the $1.41 estimate.
At a glance
A balance sheet — strong enough to weather a downturn
100/100 earnings predictability — you can trust these numbers
19.1x trailing p/e — priced about right
1.8% dividend yield — cash in your pocket every quarter
26.0% return on capital — every dollar works hard here
xvary composite: 73/100 — average
What they do
Zoetis sells medicines, vaccines, diagnostics, and testing tools for pets and farm animals.
Zoetis wins because animal health is sticky. Once your vet trusts a product, switching is a hassle for the clinic and a risk for the animal. That shows up in the numbers: a 45.0% operating margin and 26.0% return on capital mean the company keeps a lot of each dollar and reinvests it at high rates.
How they make money
$9.5B
annual revenue · their business grew +2.3% last year
U.S. companion animal
$3.40B
+7.0%
International companion animal
$2.40B
+6.0%
U.S. livestock
$1.50B
2.0%
International livestock
$1.90B
+1.0%
Diagnostics and precision animal health
$0.30B
+10.0%
The products that matter
pet dermatology treatment
Apoquel
flagship companion-animal franchise
it sits inside a $9.5B portfolio that still produced a 29.9% net margin. the exact product revenue is not broken out here, which tells you to focus on portfolio durability more than one headline number.
key product
flea, tick, and parasite protection
Simparica franchise
core pet-health category
this is part of the companion-animal engine supporting a business with 100/100 earnings predictability. when pet demand softens, products like this are where investors feel it first.
companion animal
vaccines and herd-health products
Livestock portfolio
farm and production animal exposure
livestock gives zoetis more than one end market, which matters in a company doing $9.5B of annual revenue. it also means you are exposed to farm economics, not just pet owners.
portfolio balance
Key numbers
45.0%
operating margin
Operating margin → money left after running the business → Zoetis keeps almost half of revenue before interest and taxes.
26.0%
return on capital
Return on capital → profit from each dollar invested → management turns reinvestment into growth better than most companies.
$9.5B
annual revenue
This is the actual size of the business today, and it only grew 2.3%, which is the tension in the story.
19.1x
trailing p/e
P/E → price compared with last year's earnings → you are paying a quality premium, but not a bargain price.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 80 / 100
- long-term debt $7.1B (12% of capital)
- net profit margin 30.3% — keeps 30 cents of every dollar in revenue
- return on equity 43% — $0.43 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in ZTS 3 years ago → it's now worth $8,400.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Zoetis posted Q4 adjusted EPS of $1.48, ahead of the $1.41 estimate.
Quarterly sales were $2.387B in Q4 2025, and management said cost cuts and efficiency gains helped offset softer top-line demand. That matches the broader pattern: earnings are holding up better than revenue.
$2.39B
revenue
$1.48
eps
71.9%
gross margin
the number that mattered
The key number was the $1.48 EPS beat, because it showed Zoetis can still expand profit through efficiency even when sales growth stays soft.
-
zoetis’ third-quarter results were mixed versus expectations.
-
adjusted earnings improved 8% from a year ago, to $1.70 a share.
-
the tally surpassed our estimate of $1.64, with much of the upside coming from cost cutting and benefits from efficiency initiatives.
-
this helped to mitigate some softness on the top line, as total sales edged up slightly versus the comparable year-ago period, but missed our estimate by about $40 million.this could be attributed to a combination of macroeconomic and operational challenges, including weaker pet-related demand and distributor re-stocking issues.
-
we are maintaining our full-year adjusted earnings call of $6.35 a share.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is companion-animal spending softness and distributor inventory swings — the same issue that showed up in the latest quarter.
med
pet demand stays soft
zoetis already flagged weaker pet-related demand. if clinic traffic or owner spending stays pressured, the higher-visibility companion-animal franchise stops looking like a growth engine and starts looking like a defensive one.
impact: pressure would hit a business doing $9.5B in annual revenue, and the market would care because the stock is owned for consistency.
med
distributor destocking distorts demand
inventory corrections can make real demand look weaker than it is for a quarter or two. they can also do the opposite later. that makes clean read-throughs harder, and high-predictability stocks get punished when visibility slips.
impact: even if end demand is intact, messy channel timing can pressure reported revenue growth that was only 2.3% last year.
med
margin support from cost cutting has limits
the latest earnings beat leaned in part on expense control. that works for a while. it does not replace healthier volume growth forever.
impact: with net margin already at 29.9%, the next leg up has to come more from demand than from trimming costs.
if pet demand stays weak and channel inventories keep moving around, pressure lands on the full $9.5B revenue base. the cushion is a 29.9% net margin and an A balance sheet, but quality does not make a slowdown invisible.
source: institutional data · regulatory filings · risk analysis
Pay attention to
growth
whether revenue gets back above 2.3%
last year was a low-growth year. if sales stay stuck near that pace, the stock keeps looking like a quality compounder with less compounding.
risk
companion-animal demand signals
management already flagged softness in pet-related demand. you want to hear that pressure easing, not becoming the recurring explanation.
trend
earnings beats driven by revenue, not just costs
$1.70 adjusted EPS beat the $1.64 estimate, but cost cutting helped. the next cleaner signal is demand doing more of the work.
calendar
next earnings report
one quarter will not settle the debate. the next update matters because this story is now about reacceleration versus stagnation.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts do not see a strong near-term edge either way.
risk profile
above average
stability score 2 — safer than roughly 80% of stocks. not risk-free, just sturdier than most.
chart momentum
below average
technical score 4 — the chart has not earned the market's trust back yet.
earnings predictability
100 / 100
this is as reliable as it gets. you usually do not get a lot of drama here, which is exactly why the recent slowdown matters.
source: institutional data
Institutional activity
716 buyers vs. 974 sellers in 3q2025. total institutional holdings: 0.4B shares.
source: institutional data
Price targets
3-5 year target range
$104
$213
$121
current price
$159
target midpoint · +31% from current · 3-5yr high: $235 (+95% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive